Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Business News, In Brief

Executive Summary

Celgene ups 2010 guidance; Revlimid drives growth: Celgene increased its guidance for the year, with total revenues expected to grow about 25 percent year-over-year to $3.3 billion-$3.4 billion, up from a previous range of $3.2 billion-$3.3 billion, execs said during a first quarter earnings call April 29. The biopharma also expects sales of the cancer product Revlimid (lenalidomide) to grow 30 percent year-over-year, ranging from $2.2 billion-$2.3 billion. Leerink Swann analysts seemed encouraged by Revlimid's growth potential. "We believe the presentations of the CALGB-100104 and IFM-05-02 trials on maintenance in the post-stem cell transplant setting" at the ASCO annual scientific meeting "could be important catalysts for adoption of Revlimid in this setting," they said in a same day note. "A previous MEDACorp survey following the release of the CALGB data in late December 2009 showed that 89 percent (33 of 37) of hematologists/oncologists surveyed indicated they would increase their use of Revlimid in this setting as a result of the trial," they added. For the quarter, Revlimid brought in global sales of $530.5 million, up 46 percent

You may also be interested in...

Vyvanse Adds 14-Hour Duration Data As Shire's ADHD Drugs Face Off With Generics

Duration of use data will help to strengthen Vyvanse's position in the fast-growing adult segment, Shire says.

PAH Market Heats Up: New Approvals For Actelion, United Therapeutics

With a Risk Evaluation and Mitigation Strategy for Tracleer now approved by FDA, Actelion can maximize the drug's selling potential across a broader range of pulmonary arterial hypertension patients before it faces generics in 2015

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts